Identification of a Rare PSEN1 Mutation (Thr119Ile) in Late-Onset Alzheimer’s Disease With Early Presentation of Behavioral Disturbance

Shouzi Zhang, Xiang Li, Li Zhang, Xiangyan Meng, Li Ma, Guangze Zhang, Haiyan Wu, Ling Liang, Meng Cao, Fan MeiFrontiers in Psychiatry 2020 · DOI

TL;DR

Researchers have identified a rare mutation in the PSEN1 gene, named Thr119Ile, in a Chinese family with late-onset Alzheimer's disease (AD). This mutation is linked to an unusual presentation of AD, characterized by early behavioral disturbances and executive dysfunction rather than the typical memory loss, expanding our understanding of AD's genetic and clinical diversity.

What Problem Does This Paper Address?

Alzheimer's disease (AD) is the most prevalent form of neurodegenerative dementia, characterized by the accumulation of amyloid plaques and neurofibrillary tangles. While typical AD presents with insidious memory decline, a significant subset of patients (6-14%) exhibit atypical clinical features. These can include posterior cortical atrophy, logopenic aphasia, or a frontal variant of AD, which manifests as behavioral and executive function impairments, often overlapping with psychiatric disorders or frontotemporal dementia. Understanding the genetic underpinnings of this phenotypic diversity is crucial for accurate diagnosis and developing targeted therapies. Familial AD, accounting for 1-2% of cases, is often caused by mutations in genes like PSEN1, PSEN2, and APP. While whole-exome sequencing is common for identifying pathogenic variants, it may not fully capture the contribution of other genetic factors to diverse AD presentations. This study aims to identify the genetic cause of AD in a family with an atypical, late-onset presentation and early behavioral disturbances.

Methods

The researchers employed a multi-pronged approach:

  • Whole Genome Sequencing (WGS): This was the primary technique used to analyze the entire genome of affected individuals (III-4 and III-5) from the index family. The goal was to identify rare coding mutations in genes known to be associated with various forms of dementia.
  • Bioinformatic Filtering: Raw WGS data underwent rigorous filtering. This included removing common variants (minor allele frequency > 0.1%) present in large population databases (1000 Genomes Project, dbSNP, ExAC, etc.). Variants were further filtered based on their predicted functional consequences (missense, nonsense, splice variants, indels) and mode of inheritance (dominant).
  • Sanger Sequencing: This traditional sequencing method was used to validate the identified PSEN1 mutation in other affected family members and confirm its presence.
  • APOE Genotyping: This was performed to assess the presence of the APOE ε4 allele, a known risk factor for AD, in the affected individuals.
  • Neuroimaging and PET Scanning: Cranial MRI was used to assess brain structure, and 11C-PiB PET scans were performed to detect amyloid deposition, a hallmark of AD pathology.
  • Clinical and Neuropsychological Assessments: Affected individuals underwent detailed neurological examinations, neuropsychological testing (MMSE, MoCA, CDR, NPI, etc.), and assessment of daily living activities.

Datasets

  • Human Genome Databases: The study utilized publicly available human genome databases for variant filtering, including:
  • 1,000 Genome Project
    • Single Nucleotide Polymorphism database (dbSNP)
    • NHLBI-GO Exome Sequencing Project (ESP6500)
    • Exome Aggregation Consortium (ExAC) database
  • Ensembl Database: Used for annotating genetic variants.
  • Family Pedigree Data: The study involved a four-generation pedigree with eight affected individuals, providing a dataset for family-based genetic analysis.

Key Insights and Ideas

  • PSEN1 as a Causal Gene for Atypical AD: The study strongly implicates a rare PSEN1 mutation as the cause of AD in this family, despite the atypical clinical presentation. This highlights that PSEN1 mutations can manifest in diverse ways beyond the classic amnestic form.
  • Behavioral Disturbance as an Early AD Symptom: The identification of early and prominent psychiatric symptoms and executive dysfunction in individuals with this PSEN1 mutation underscores the importance of considering behavioral changes as potential early indicators of AD, particularly in familial cases.
  • Broadening the Spectrum of PSEN1 Mutations: The discovery of the Thr119Ile mutation in PSEN1 expands the known repertoire of PSEN1 variants associated with AD, contributing to a more comprehensive understanding of the genetic landscape of familial AD.
  • Functional Significance of the Hydrophilic Loop: The mutation occurs in the first hydrophilic loop of the PSEN1 protein. This region is known to be critical for protein function and interaction with APP, suggesting that alterations here can significantly impact AD pathogenesis.

Key Results

  • Identification of PSEN1 c.356C>T (p.T119I) Mutation: Whole genome sequencing identified a single rare missense mutation in the PSEN1 gene in affected individuals III-4 and III-5. This mutation was validated by Sanger sequencing in other affected family members.
  • Atypical Clinical Presentation: The proband (III-5) and other affected individuals presented with late-onset AD (onset around age 68-74) characterized by early executive dysfunction, apathy, behavioral disinhibition, verbal aggression, and irritability, rather than primary memory loss.
  • Positive Amyloid PET: The proband's 11C-PiB PET scan showed profound bilateral uptake of amyloid tracer, confirming the presence of AD pathology.
  • Exclusion of Other Genetic Factors: The comprehensive WGS analysis excluded rare mutations in other known susceptible genes for dementia and structural variations in APP, reinforcing PSEN1 as the primary genetic cause.
  • Predicted Pathogenicity: Bioinformatic tools predicted the T119I substitution to be "probably damaging" and "disease causing," suggesting a significant functional impact.
  • Late Onset Despite Mutation Location: Interestingly, carriers of this mutation presented with late-onset AD, which is somewhat contrary to the general observation that mutations in the first hydrophilic loop of PSEN1 are often associated with early-onset AD. This suggests the presence of other genetic or environmental factors that may have delayed symptom onset.

Limitations and Future Work

  • Limitations:
    • Limited Clinical Data for Deceased Individuals: For some deceased affected family members, detailed clinical information was based on medical history provided by relatives, which may lack the precision of direct clinical assessment.
  • Severe Dementia at Assessment: When some affected individuals were assessed, they were already in advanced stages of dementia, making it difficult to fully characterize their early behavioral changes.
  • Lack of Autopsy Data: The absence of autopsy data prevents direct characterization of the pathological features of this frontal variant of AD in this pedigree.
  • Potential for Non-AD Pathology: While amyloid PET was positive, the authors acknowledge that other pathologies might contribute to the atypical presentation.
  • Future Work:
    • Biological Experiments: The authors suggest that biological experiments are warranted to examine the functional impact of the T119I mutant on amyloid production and neuroplasticity.
  • Further Investigation of Protective Factors: Understanding the factors that might have delayed the onset of AD in this late-onset pedigree could provide valuable insights.
  • Broader Phenotypic Characterization: Continued research on other families or sporadic cases with the T119I mutation would help to further define its phenotypic spectrum.

Summary updated

Abstract

Alzheimer's disease (AD) is the most common form of neurodegenerative dementia. In this study, whole genome sequencing identifies one rare and likely pathogenic mutation in the <i>presenilin 1 (PSEN1)</i> gene (c.356C > T, p.T119I) associated with a frontal variant of AD. Affected individuals in the kindred developed late-onset cognitive decline accompanied with early presentation of psychiatric symptoms. Positive amyloid PiB PET tracing suggested presence of pathophysiological biomarker for AD. Whole genome sequencing analysis evaluated rare coding mutations in susceptible genes for various types of dementia and supported the role of <i>PSEN1</i> as a causal gene. Identification of this T119I variant in <i>PSEN1</i> might broaden the spectrum of genetic basis and clinical diversity of familial AD.
BibTeX
@inproceedings{zhang2020identification,
  author = {Shouzi Zhang and Xiang Li and Li Zhang and Xiangyan Meng and Li Ma and Guangze Zhang and Haiyan Wu and Ling Liang and Meng Cao and Fan Mei},
  title = {{Identification of a Rare PSEN1 Mutation (Thr119Ile) in Late-Onset Alzheimer’s Disease With Early Presentation of Behavioral Disturbance}},
  booktitle = {Frontiers in Psychiatry},
  year = {2020},
  doi = {10.3389/fpsyt.2020.00347},
}
Figure